Comparative Outcomes of Primary Sclerosing Cholangitis With and Without Comorbid Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Dig Dis SciMay 5, 2026 (epub)
Bachviet Nguyen, Stephanie Quon, Daljeet Chahal
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated clinical outcomes in 23,837 patients with primary sclerosing cholangitis (PSC), comparing those with inflammatory bowel disease (IBD) to those without. The study found that PSC-IBD is associated with a significant decrease in all-cause mortality or liver transplantation (HR 0.77, 95% CI 0.62-0.97).
Key findings
- PSC-IBD patients had a lower risk of all-cause mortality or liver transplantation (HR 0.77, 95% CI 0.62-0.97).
- Patients with PSC and Crohn's disease had a significantly lower risk of all-cause mortality or liver transplantation (HR 0.67, 95% CI 0.54-0.84).
- PSC-IBD was associated with an increased risk of hepatopancreatobiliary cancer (HR 2.37, 95% CI 1.35-4.15).
- No significant difference in risk of recurrent PSC was found between PSC-IBD and PSC only.
Why it matters
Understanding the comparative outcomes of PSC with and without IBD is crucial for risk stratification and management of patients. This study provides insights that may influence clinical decision-making regarding monitoring and treatment strategies.